9 Results for "

SET 2

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "SET 2" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-132222
CAS No.: 2313525-20-9
Purity:  99.78%
Target:  

TRP Channel

Research Areas:  

Cancer

SET2 is a selective TRPV2 antagonist (IC50=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N5024
CAS No.: 173932-75-7
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-131906
CAS No.: 2593402-36-7
Purity:  99.15%
Target:  

JAK FLT3 Apoptosis

Research Areas:  

Cancer

JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .
loading...
    loading...
Cat. No.: HY-101508
CAS No.: 1385035-79-9
Purity:  98.02%
Research Areas:  

Cancer

GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .
loading...
    loading...
Cat. No.: HY-162308
CAS No.: 744260-15-9
Research Areas:  

Cancer

NSD-IN-3 (compound 3) is a potent nuclear receptor binding SET domain (NSD) inhibitor. NSD-IN-3 inhibits NSD2-SET and NSD3-SET with IC50 values of 0.81 μM and 0.84 μM, respectively. NSD-IN-3 inhibits histone H3K36 dimethylation and decreases the expression of NSDs-targeted genes in non-small cell lung cancer cells. NSD-IN-3 induces s-phase cell cycle arrest and apoptosis .
loading...
    loading...
Cat. No.: HY-155818
CAS No.: 3035028-80-6
Research Areas:  

Cancer

NSD2-IN-4 is a potent and selective NSD2-SET inhibitor. NSD2-IN-4 has the potential for NSD2-related diseases .
loading...
    loading...
Cat. No.: HY-P88284
Synonyms: HBP231; HIF-1; HIP-1; HSPC069; HYPB; KMT3A; LLS; p231HBP; SET2

Host:  

Mouse

Application:  

IHC-P

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-P88284A
Synonyms: HBP231; HIF-1; HIP-1; HSPC069; HYPB; KMT3A; LLS; p231HBP; SET2

Host:  

Mouse

Application:  

IHC-P

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-182486
CAS No.: 1212675-57-4
Research Areas:  

Cancer

LEM-06 is an NSD2 inhibitor with a human IC50 of 890 μM and 0.8 mM. LEM-06 binds to the histone-tail binding groove of NSD2-SET, inhibiting NSD2-mediated H3K36 histone methyltransferase activity and H3K36 mono-methylation. LEM-06 serves as a hit molecule for further optimization or derivation to explore NSD2 biology. LEM-06 can be used for the research of multiple myeloma .
loading...
    loading...